Information Library

Results for: Clinical Services - Phase II/III - Africa

In the complex environment of the New Health, Quintiles is committed to helping you succeed. At every stage of your product’s lifecycle, we are dedicated to delivering real results, being proactive in navigating issues and thinking of new solutions.  Search our library today.

Start Over

  • Sort by:
  • Recently Added
  • Title

  • Energizing Enrollment

    Case Study — October 4, 2011
    The rapid recruitment for this Phase III, open, randomized, controlled, multi-center study in adjuvant triple-negative breast cancer (TNBC) was completed two months earlier than planned.

  • Partnering is Key to Maximizing Rewards in Emerging Markets

    Press Release — September 27, 2011 – While biopharmaceutical spending in emerging markets is growing at double-digit rates – much faster than in developed nations – opportunities in “pharmerging” countries must be balanced with accompanying costs and risks of entering new markets.

  • Malaria Prevention in Sub-Saharan Africa

    Case Study — June 24, 2011
    This study enabled us to be involved in bringing a malaria vaccine to Africa which could substantially reduce an infant mortality rate that currently stands

  • Constant Vigilance

    Case Study — March 16, 2011
    Centralized planning played a key role in improving productivity during site visits and close monitoring ensured the high standards Quintiles put in place were met.

  • Recruiting Trust

    Case Study — March 16, 2011
    Quintiles enrolls 2 cancer trials, 2 times faster than projected

  • Acute Coronary Syndrome - Tailored Solutions

    Case Study — February 1, 2011
    Find out how our experience in multi-national cardiovascular clinical trials helped this customer reach database lock 66 days after LPO.

  • Managing Trauma

    Case Study — September 14, 2010
    Quintiles overcame the unpredictability of patient recruitment due to the emergency setup and the client was able to file for approval based on phase II data only.

  • New FDA Guidance on Antidiabetic Therapies

    White Paper — December 11, 2009
    Understanding the FDA Guidance on Assessing Cardiovascular Risks for new Antidiabetic Therapies. Learn what FDA cardiac safety requirements may mean for your development program.

  • Coordinating Safety Across Functions and Phases

    Case Study — November 3, 2009
    Facing significant challenges with clinical and post-marketing safety, a customer needed an ally who could provide a full range of safety and risk management solutions.

Page 1 of 1 (9 results)

Subscribe to Email Based on Your Interests

Set preferences